Here’s what you should know:
1. Valeant’s sales decreased 10 percent or $260 million, year-over-year.
2. Valeant reported net income of $1.30 billion for the third quarter.
3. The company’s gastroenterology segment, Salix, grew its revenues by 3 percent year-over-year. Excluding foreign exchange and divestitures, revenue grew 6 percent year-over-year.
4. The company’s Bausch + Lomb segment increased revenue by 1 percent year-over-year. When excluding foreign exchange and divestitures, revenue also grew 6 percent year-over-year.
5. Valeant CEO Joseph C. Papa said in a release, “Our strong third-quarter performance demonstrates our continued progress in the turnaround of Valeant. Driven by solid execution in our Bausch + Lomb/International segment and our Salix business, we delivered strong organic revenue growth across approximately 77% of our business in the quarter.”
6. Concerning end-of-year outlooks, Valeant anticipates net income between $8.70 billion to $8.90 billion. Valeant raised its full-year revenue expectations from the previous quarter.
More articles on gastroenterology:
GI center to know: River Oaks Endoscopy
Takeda, Mederi Therapeutics & more — 6 GI company key notes
AmSurg recognizes 45 ASCs for quality, efficiency
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
